NVDA vs PFE: Which Is the Better Buy?

Side-by-side comparison of NVIDIA Corporation and Pfizer Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-26.
NVIDIA Corporation ยท Technology
$225.07
+45.0% upside to fair value
Med Conviction Grade B High Quality
VS
Pfizer Inc. ยท Healthcare
$27.64
+12.0% upside to fair value
Med Conviction Grade B
QuantHub Verdict
NVDA has more upside to fair value (+45.0%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric NVDA PFE
Current Price $225.07 $27.64
Fair Value Estimate $326.35 $30.94
Upside to Fair Value +45.0% +12.0%
Market Cap $5,451.4B $157.5B
Forward P/E โ€” โ€”
EV / EBITDA 23.4x 17.4x
Price / Sales 18.0x 2.5x
Price / FCF 42.9x 14.3x
Revenue Growth YoY +105.9% +2.6%
Gross Margin 74.7% 71.3%
Operating Margin 65.2% 25.1%
Return on Equity 110.1% 4.9%
Dividend Yield 0.23% 6.22%
FCF Yield 2.33% 6.97%
Analyst Consensus Strong Buy Hold
Investment Thesis
NVDA โ€” NVIDIA Corporation
NVIDIA designs the accelerated computing platforms at the center of the AI buildout, spanning data center GPUs, Mellanox networking, AI enterprise software, gaming GeForce GPUs, professional visualization, and automotive platforms, with 42,000 employees and a $5.45 trillion market capitalization. Business quality is exceptional on the fundamentals: TTM gross margin of 74.7%, TTM operating margin โ€ฆ
PFE โ€” Pfizer Inc.
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating โ€ฆ
Accumulation Zones
Metric NVDA PFE
Zone Low $244.76 $23.21
Zone High $277.40 $26.30
In Buy Zone? Yes No
โ† NVDA Research    PFE Research โ†’    All Research